Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Appointed director
Inv. presentation
|
|
Molecular Templates, Inc. (MTEM)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/10/2023 |
8-K
| Quarterly results|
Docs:
|
"Molecular Templates, Inc. Reports Second Quarter 2023 Financial Results and Business Update AUSTIN, Texas, Aug. 10, 2023 -- Molecular Templates, Inc. , a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies , to create novel therapies with potent differentiated mechanisms of action for cancer, today reported financial results and business updates for the second quarter of 2023. Eric Poma, PhD., Chief Executive and Chief Scientific Officer of MTEM, stated, “ETBs represent a novel approach to the treatment of cancer with differentiated biology and unique mechanisms of action. We expect to see substantial data across all three of our clinical programs with updates throughout this year and into ..." |
|
| 05/15/2023 |
8-K
| Quarterly results |
| 11/10/2022 |
8-K
| Quarterly results |
| 08/11/2022 |
8-K
| Quarterly results |
| 05/12/2022 |
8-K
| Quarterly results |
| 03/29/2022 |
8-K
| Quarterly results|
Docs:
|
"Molecular Templates, Inc. Reports Fourth Quarter 2021 Financial Results AUSTIN, Texas, March 28, 2022 -- Molecular Templates, Inc. , a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies , today reported financial results for the fourth quarter of 2021. “2022 is off to a very promising start, following a number of important developments across our pipeline of ETBs in 2021,” said Eric Poma, Ph.D., Chief Executive and Chief Scientific Officer of Molecular Templates. “We continue to see differentiated pharmacodynamic effects and evidence of antigen seeding with MT-6402 with additional data expected throughout 2022. We continue dose finding for the MT-5111 and MT-0169 programs with clinical dat..." |
|
| 11/15/2021 |
8-K
| Quarterly results|
Docs:
|
"Molecular Templates, Inc. Reports Third Quarter 2021 Financial Results AUSTIN, Texas, Nov. 15, 2021 -- Molecular Templates, Inc. , a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies , today reported financial results for the third quarter of 2021. “We are focused on execution across our growing portfolio of wholly owned next-generation ETBs,” said Eric Poma, Ph.D., Molecular Templates’ Chief Executive and Scientific Officer. “Third quarter highlights included the initiation of clinical development of MT-6402 , the initiation of the HER2-positive breast cancer expansion cohort for MT-5111 as well as continued enrollment of patients in our MT-0169 clinical program. These programs demonstra..." |
|
| 08/12/2021 |
8-K
| Quarterly results|
Docs:
|
"Molecular Templates, Inc. Reports Second Quarter 2021 Financial Results AUSTIN, Texas, Aug. 12, 2021 -- Molecular Templates, Inc. , a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies , today reported financial results for the second quarter of 2021. “We continue to make progress on advancing our wholly owned pipeline of next-generation ETBs and our existing partnerships. We reached an important milestone recently with initiation of clinical development of MT-6402 which is the first of our third generation ETBs to enter the clinic,” said Eric Poma, Ph.D., Molecular Templates’ Chief Executive and Scientific Officer. “With regard to TAK-169, we are now looking forward to continuing clinical..." |
|
| 03/18/2021 |
8-K
| Quarterly results |
| 11/05/2020 |
8-K
| Quarterly results |
| 08/06/2020 |
8-K
| Quarterly results |
| 05/11/2020 |
8-K
| Quarterly results|
Docs:
|
"Molecular Templates, Inc. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended March 31, 2020 2019 Research and development revenue - from related party $ 333 $ 6,413 Research and development revenue - other 1,467 — Grant revenue 2,341 595 Total revenue 4,141 7,008 Operating expenses: Research and development 20,631 8,454 General and administrative 5,647 4,935 Total operating expenses 26,278 13,389 Loss from operations 22,137 6,381 Interest and other income, net 472 510 Interest and other expense, net Change in fair value of warrant liabilities — Loss before provision for income taxes 22,013 6,168 Provision for income taxes 5 — Net loss 22,018 6,168 Net loss attributable to common shareholders $ 22,018 $ 6,168 Net loss per share attributable to common shareholders: Basic an..." |
|
| 03/12/2020 |
8-K
| Quarterly results |
| 11/12/2019 |
8-K
| Quarterly results |
| 08/12/2019 |
8-K
| Quarterly results|
Docs:
|
"Molecular Templates, Inc. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 Research and development revenue – from related party $ 5,211 $ 932 $ 11,624 $ 1,095 Research and development revenue – other — 12 — 80 Grant revenue 236 423 831 674 Total revenue 5,447 1,367 12,455 1,849 Operating expenses: Research and development 10,243 7,662 18,697 14,350 General and administrative 4,605 3,718 9,540 6,627 Total operating expenses 14,848 11,380 28,237 20,977 Loss from operations 9,401 10,013 15,782 19,128 Interest and other income, net 543 118 1,053 200 Interest expense Change in fair value of warrant liabilities 6 298 2 912 Net loss attributable to common shareholders $ 9,153 $ 9,695 $ 15,321 $ 18,409 Net loss per share ..." |
|
| 05/13/2019 |
8-K
| Quarterly results |
| 03/28/2019 |
8-K
| Quarterly results |
| 11/13/2018 |
8-K
| Quarterly results|
Docs:
|
"Molecular Templates, Inc. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS 10-Q Three Months Ended September 30, 10-Q Nine Months Ended September 30, 2018 2017 2018 2017 Research and development revenue $ 2,031 $ 648 $ 3,206 $ 2,408 Grant revenue 4,721 — 5,395 167 Total revenue 6,752 648 8,601 2,575 Operating expenses: Research and development 8,290 2,522 22,640 4,829 General and administrative 3,538 3,996 10,165 8,233 Total operating expenses 11,828 6,518 32,805 13,062 Loss from operations 5,076 5,870 24,204 10,487 Interest and other income, net 107 1 307 2 Interest expense Change in fair value of warrant liabilities 4 916 Loss on conversion of notes — — Net loss 5,244 10,967 23,653 16,225 Deemed dividends on preferred stock — — Net loss attributable to common shareholders $ 5,244 $ 11,..." |
|
| 08/09/2018 |
8-K
| Quarterly results |
| 05/14/2018 |
8-K
| Quarterly results |
| 03/28/2018 |
8-K
| Quarterly results |
| 05/15/2017 |
8-K
| Form 8-K - Current report |
| 03/27/2017 |
8-K
| Form 8-K - Current report |
| 11/07/2016 |
8-K
| Quarterly results |
| 08/01/2016 |
8-K
| Form 8-K - Current report |
| 05/05/2016 |
8-K
| Quarterly results |
| 03/10/2016 |
8-K
| Form 8-K - Current report |
| 11/02/2015 |
8-K
| Quarterly results |
| 07/30/2015 |
8-K
| Quarterly results |
| 04/30/2015 |
8-K
| Quarterly results |
| 03/03/2015 |
8-K
| Quarterly results |
| 11/03/2014 |
8-K
| Quarterly results |
| 08/01/2014 |
8-K
| Quarterly results |
| 05/01/2014 |
8-K
| Quarterly results |
|
|
|